Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Overall venture investment in the sector remains steady, but the big strategics back off.
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
With most glimmers of hope extinguished in the third quarter, 2022 is shaping up to be an annus horribilis for sector share prices.
Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.